AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’
Shares of Axsome Therapeutics (AXSM) rose 6% on Friday after Mizuho analyst Graig Suvannavejh said August prescription data pointed to a strong start for the drug’s newest use.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.